Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Cardiac MRI & Biomarkers in Friedreich's ataxia

Description: The study is recruiting children and adults ages 10-50 with Friedreich's Ataxia for a study of Cardiac MRI & Biomarkers in Friedreich's ataxia to learn more about heart disease in Friedreich’s ataxia (FA) through new blood and imaging tests.

Key Criteria: Ages 10-50 years

Location: Children's Hospital of Philadelphia (CHOP)

Please review the study flyer below, and contact the Study Coordinator with any questions.
 


Can't see this document? Click Me

 

 

Exercise in Friedreich's ataxia

Description: The study is recruiting children and adults ages 8-40 with Friedreich's Ataxia for a study of Exercise in Friedreich's ataxia to determine if there is a relationship between exercise performance, neurologic status, cardiac status and global functioning.

Key Criteria: Ages 8-40 years

Location: Children's Hospital of Philadelphia (CHOP)

Please review the study flyer below, and contact the Study Coordinator with any questions.
 


Can't see this document? Click Me

 

 

Horizon's Actimmune Phase 3 Trial

Phase III, double-blind, placebo-controlled study of interferon gamma-1b (ACTIMMUNE®) for the treatment of Friedreich’s Ataxia

Ages: 10-25

Location: Children's Hospital of Philadelphia (CHOP), University of Iowa, University of Florida (Gainesville, FL) and UCLA (Los Angeles, CA)

Details: The study is recruiting children and young adults ages 10-25 with Friedreich's Ataxia for a Phase III, double-blind, placebo-controlled clinical trial studying the safety, efficacy, and pharmacokinetics of IFN-γ (interferon gamma-1b, ACTIMMUNE) in FA. This study is funded by Horizon Pharma Ireland, Ltd. and will include approximately 90 patients at four sites in the United States.

For more information, visit the study's clinicaltrials.gov site: www.clinicaltrials.gov/ct2/show/NCT02415127

Please see the study flyers below and contact the study coordinators listed for each site with any questions.

University of Minnesota MRI Study

Description: MRI Study for people with early symptoms of FA or presymptomatic genetically confirmed individuals.
The University of Minnesota is still looking for participants who are presymptomatic or have very few symptoms of FA to complete an MRI imaging study which may help develop noninvasive diagnostic tools for FA. This is a one time visit, with a possible follow-up visit in 1 year. Reimbursement for travel expenses is available.

Key Criteria: Ages 10 and older

Location: University of Minnesota

Please review the study flyer below, and contact the Study Coordinator with any questions.
 


Can't see this document? Click Me

 

 

EPI-743 in FA Point Mutations

EPI-743 in Friedreich's Ataxia Point Mutations

Ages: 18-65

Location: University of South Florida

Details: The University of South Florida (USF) in Tampa, FL is looking for adults ages 18-65 to complete a trial for EPI-743 in patients with point mutations. This is a Phase 2A Clinical Trial for Edison Pharmaceutical's EPI-743, also known as Vincerinone™, which aims to improve mitochondrial function by reducing oxidative stress. All participants will receive 400mg of EPI-743 three times daily for 3 months. The sponsor of the trial is Edison Pharmaceuticals, Inc. and the study's lead investigator is Theresa Zesiewicz, MD.

To be eligible for participation, genetic confirmation of Friedreich’s Ataxia is required. Additional eligibility details are available at: www.clinicaltrials.gov/ct2/show/NCT01962363

If you are interested in participating, please contact the study coordinator below:

Page 3 of 4

SHARE

FacebookTwitterLinkedInYoutube
Event G.jpg
Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator